# Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

> **NCT04030429** · PHASE2 · TERMINATED · sponsor: **National Cheng-Kung University Hospital** · enrollment: 40 (actual)

## Conditions studied

- Endometrial Cancer Recurrent

## Interventions

- **DRUG:** Crizotinib 250 MG

## Key facts

- **NCT ID:** NCT04030429
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Patients were recruited during screen phase but fewer patients met criteria.
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04030429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04030429, "Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04030429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*